Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by a mutation in the Huntingtin gene (HTT) that results in an increase in the number of glutamine-encoding CAG repeats. 1, 2 When the mutant Htt (mHtt) protein contains >39 glutamine repeats, the illness manifests itself by the onset of cognitive and psychiatric disturbances followed by the progressive development of motor symptoms such as chorea. HD histopathology presents with a significant loss of medium-sized spiny neurons (MSNs) in the striatum and in its innervation arising from cortical pyramidal neurons (CPNs). Methods: Whole-cell patch clamp recordings of CPNs in slices from symptomatic R6/2 mice and wild-type (WT) littermates were used to examine the effects of selective or concurrent inhibition of glutamate reuptake transporters.
| INTRODUC TI ON
Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by a mutation in the Huntingtin gene (HTT) that results in an increase in the number of glutamine-encoding CAG repeats. 1, 2 When the mutant Htt (mHtt) protein contains >39 glutamine repeats, the illness manifests itself by the onset of cognitive and psychiatric disturbances followed by the progressive development of motor symptoms such as chorea. HD histopathology presents with a significant loss of medium-sized spiny neurons (MSNs) in the striatum and in its innervation arising from cortical pyramidal neurons (CPNs). 3 The corticostriatal pathway is critically involved in movement control, and brain imaging studies in presymptomatic HD carriers have shown that cortical atrophy occurs early, develops progressively, and correlates with the expression and severity of cognitive and motor symptoms. [4] [5] [6] [7] More recent studies have shown that when the expression of mHtt is switched off only in CPNs, the electrophysiological alterations in MSNs are improved, thus reducing the motor phenotype in a conditional HD mouse model. 8, 9 Altogether this evidence suggests that CPNs play a crucial role in the etiology of HD (for review, see 10 ). Therefore, understanding the synaptic changes underlying aberrant functioning of CPNs in HD might provide novel drug targets to improve HD symptoms.
Central to CPN alterations is the failure of the glutamate reuptake system during glutamatergic neurotransmission. This system functions to regulate the synaptic concentration of glutamate in order to avoid its accumulation and spillover, which in turn could initiate an excitotoxic neuronal death cascade (for review, see ref. 11 ). Glutamate transporter 1 (GLT-1) and glutamate aspartate transporter (GLAST) are proteins expressed predominantly in astrocytes, although GLT-1 is also expressed in neuronal terminals, and they take up glutamate after its release from presynaptic terminals. 12, 13 In addition to preventing glutamate accumulation, proper functioning of glutamate transporters is essential to ensure efficient neuronal transmission and flow of information 14, 15 . Decreased GLT-1 mRNA and protein levels have consistently been reported in the striatum and cortex of postmortem HD brains and transgenic mouse models. [16] [17] [18] [19] [20] [21] While consistent alterations have been observed in GLT-1, less is known about changes in GLAST. Although some studies have shown decreased GLAST protein expression, others describe no changes in protein content. 17, 18, 20, 21 Nevertheless, the reduction in protein content of both GLT-1 and GLAST in the cortex of HD patients and animal models could render the striatum more vulnerable to glutamate-induced neurotoxicity. 21, 22 Together, this evidence suggests that failure of glutamate reuptake might contribute to the impaired cortical processing described in HD models both in vitro and in vivo. [23] [24] [25] [26] [27] However, the precise effects of faulty glutamate reuptake on excitatory inputs to CPNs remain to be explored. In the present study, we evaluated changes induced by partial or complete blockade of the glutamate reuptake transporters. Evoked and spontaneous excitatory postsynaptic currents (eEPSCs and sEPSCs) were recorded in layer 2/3 CPNs from symptomatic R6/2 transgenic mice (10-12 weeks of age) and wild-type (WT) littermates.
| ME THODS

| Animals and genotyping
Experimental procedures were performed under the United States Public Health Service Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care
Committee at the University of California, Los Angeles (UCLA). All efforts were made to minimize suffering and the number of animals used. WT and R6/2 mice were from our breeding colony at UCLA.
Mice were housed under controlled temperature (21-24ºC) and humidity conditions (30%-60%) and maintained on a 12-h light/dark cycle with free access to food and water. For this study, we used a total of 45 male or female mice (n = 19 WT and n = 26 R6/2), at an average age of 75±5 days for WT and 74±3 days for R6/2 (t = 0.089, df = 43, P = 0.929). Mouse genotyping was performed using DNA obtained from tail samples collected at weaning [for more details about genotyping procedures, see 28 ] . After completion of electrophysiological recordings, mouse genotypes were corroborated by a secondary, blind genotyping process. The mean number of CAG repeats was 151±2 as determined by Laragen Inc (Culver City, CA).
| Slice preparation and electrophysiological recordings
Mice were deeply anesthetized with isoflurane and intracardially perfused with ice-cold high-sucrose solution that had been oxygenated with 95% O 2 -5% CO 2 . After removing the brain, it was immediately placed in the same oxygenated high-sucrose slice solution. 
| Data analysis and statistics
As no gender differences were observed, data were pooled. sEPSC data were analyzed offline, initially with an automated detection protocol using the Mini Analysis program (Justin Lee, Synaptosoft, version 6.0) and then checked manually for accuracy by an investigator blind to the experimental condition. The threshold amplitude for the sEPSC event detection was 5 pA. We quantified large-amplitude paroxysmal activity manually using a threshold of 400 pA. For the stimulation experiments, we used ClampFit software to determine peak amplitude, area, and decay time of eEPSCs. Decay time was considered the time 90%-10% of the decay phase, where 100% was the peak amplitude and 0% was the baseline. 32 In 
| RE SULTS
| Basic membrane properties of CPNs
CPNs in frontal cortex were recorded at a holding potential (V hold )
of −70 mV. CPNs from R6/2 mice displayed a significant decrease in mean cell membrane capacitance (unpaired Student's t test t = 3.72, df = 101, P = 0.0003, n = 53 WT and n = 50 R6/2), a significant increase in mean input resistance (t = 2.05, df = 101, P = 0.043), and a significant decrease in the mean decay time constant (t = 3.79, 
| Evoked responses before and during partial or complete glutamate reuptake inhibition
We examined CPN responses evoked by electrical stimulation in the proximity (200-300 μm) of the recorded cell to induce phasic release of glutamate. First, we obtained a basal response to an electrical stimulus (0.1 mA intensity, three sweeps applied every 20 s).
As shown in Figure 1A -D, R6/2 CPNs (n = 20 cells, 60 replicates) displayed significant increases in peak amplitude, area, and decay time of eEPSCs as compared with WT CPNs (n = 33 cells, 99 replicates)
[peak amplitude: t = 3.83, df = 157, P = 0.0002; area: t = 7.648, df = 157, P < 0.0001; decay time: t = 6.606, df = 157, P < 0.0001].
These results corroborate previous findings from our laboratory. 35 We next examined the effect of GLT-1 inhibition on eEPSCs.
As shown in Figure 2A , in both WT and R6/2 CPNs, the incubation with DHK led to a slight decrease (~20%) in peak amplitude as compared with their own basal response (n = 12 WT, n = 7 R6/2), but the difference between genotypes was not statistically significant.
Similarly, the area of evoked responses was reduced after incubation with the GLT-1 blocker, but again there was no significant difference between genotypes ( Figure 2B ). The reduction in evoked response area was due to a combination of reduced amplitude and, unexpectedly, a decrease in eEPSC decay time ( Figure 2C ). This could suggest that when one glutamate transporter is blocked, the other can compensate and even overcompensate for the pharmacologically induced loss of function. In contrast to what we observed during the specific blockade of GLT-1, inhibition of GLAST with UCPH-101 induced very small increases in the peak amplitude in both WT and R6/2 CPNs (n = 11 WT and n = 7 R6/2), but the difference between genotypes was not statistically significant. However, similar to DHK, the GLAST inhibitor produced small decreases in decay times, which led to negligible changes in response area. Incubation with DL-TBOA induced a slight decrease in eEPSC amplitude in both WT and R6/2
CPNs (n = 10 WT and n = 6 R6/2). However, the difference was not statistically significant between genotypes. In contrast, R6/2 neurons showed significantly larger areas and decay times relative to WTs ( Figure 2B,C) , as a consequence of the inhibition of both transporters, and this effect was significantly greater in CPNs from R6/2 mice (area: t = 3.049, df = 153, P < 0.002; decay time: t = 2.487, df = 153, P < 0.01). Figure 2D shows some example traces illustrating the significant increase in decay time in R6/2 CPNs after application of DL-TBOA.
| sEPSC frequency before and during glutamate reuptake inhibition
First, sEPSC frequency of CPNs was determined in the presence of BIC (5 μmol L −1 ) alone. sEPSC frequency was similar between WT and R6/2 CPNs (Figure 3A , B; n = 21 WT and n = 35 R6/2, P = 0.87).
Next, we evaluated the effect of DHK, UCPH-101, and DL-TBOA on the frequency of CPN sEPSCs. We observed that incubation with DHK tended to decrease the frequency of sEPSCs in R6/2 CPNs, but the resulting difference did not prove to be statistically significant Figure 3E .
We analyzed the changes in sEPSC amplitude and kinetics after the inhibition of glutamate transporters (Table 2) . DHK incubation only reduced the amplitude (t = 3.13, df = 16, P = 0.006, n = 9 WT and n = 9 R6/2), while no changes in the rise time, decay time, and half-amplitude duration occurred. Incubation with UCPH-101
and DL-TBOA failed to modify the amplitude or any of the kinetic parameters.
We also observed that some CPNs (WT = 33% and R6/2 = 45%) developed paroxysmal, epileptiform activity as a consequence of the application of glutamate reuptake blockers in the presence of BIC. We quantified the frequency of paroxysmal events (>400 pA)
induced by DHK, UCPH-101, and DL-TBOA. CPNs from R6/2 mice were more prone to develop paroxysmal-like activity during inhibition of either of the glutamate transporters ( Figure 4 ), but this increase was statistically significant only during full inhibition of the glutamate reuptake system by DL-TBOA (P = 0.048, n = 6 WT and n = 10 R6/2; Figure 4A and B). In addition, the latency to induce paroxysmal activity in the R6/2 CPNs was significantly shorter relative to WT CPNs ( Figure 4C ; t = 4.05, df = 14, P = 0.0014).
| D ISCUSS I ON
In the present study, we show that CPNs from R6/2 mice display Altogether our results suggest that CPNs in the R6/2 mice are more sensitive to compromised glutamate reuptake and that failure in this system might lead to overactivation of glutamate receptors in the frontal cortex.
Our results demonstrate for the first time that the frontal cortex also is susceptible to glutamate reuptake failure, which was reported previously in the striatum of R6/2 mice. 21 Moreover, as frontal CPNs in the R6/2 are more prone to paroxysmal activity, this brain area might be a trigger for the development of epileptic seizures observed in R6/2 mice. 35, 36 This is consistent with the finding that with disease progression, there is a progressive increase in sEPSC frequency in CPNs which is associated with reduced inhibition. 35 Interestingly, application of glutamate reuptake blockers reduced the frequency of sEPSCs in R6/2 CPNs and this effect was statistically significant when both transporters were blocked with DL-TBOA. Reduced sEPSC frequency could represent a particular form of homeostatic synaptic downscaling 37 as a result of failure of glutamate reuptake from the synaptic cleft and designed to prevent excessive activation of postsynaptic glutamate receptors. An alternative explanation could involve activation of metabotropic receptors located on the presynaptic terminals. Indeed, studies have shown that inhibition of glutamate reuptake causes a decrease in synaptic release of glutamate due to overactivation of these receptors. 12, 38 Why with disease progression these homeostatic mechanisms fail to reduce synaptic activity remains unknown. However, it was recently demonstrated that RE1-silencing transcription factor (REST) plays a critical role for the downscaling of neuronal hyperexcitability, 39, 40 and in HD, the function of REST is greatly disrupted. 41 In control conditions, before any drug application, evoked responses of R6/2 CPNs showed an increase in amplitude, area, and decay time compared with WTs, suggesting that glutamate transport is impaired in R6/2 CPNs. It is interesting that when both glutamate transporters are blocked by DL-TBOA, we only observed an increase in area and decay time, but not in the amplitude of the response.
One explanation for this outcome could be that a ceiling effect has occurred in R6/2 CPNs. In striatal neurons from HD mice, we have shown that acute blockade consistently increases decay time, whereas changes in amplitude of the response are more variable. TA B L E 2 Amplitude and kinetics of sEPSCs after glutamate transporter blockade many respects. 44, 45 For example, single neuron responses to either evoked or spontaneous activation showed a differential localization and dynamics of postsynaptic responses. 46 Therefore, glutamate reuptake inhibition could affect spontaneous and evoked EPSCs differentially.
Impaired function of the glutamate reuptake system has been described in HD, with GLT-1 as the main focus [for review, see 47 ].
Reduced functioning and protein expression of this transporter in the striatum and cerebral cortex have been described in both human HD patients and transgenic models. [16] [17] [18] [19] [20] 48 In the R6/2 model, a decrease in mRNA and protein levels of GLT-1 has been observed in the striatum and cortex at about 10 weeks of age, 17, 18 although reduced function can occur as early as 8 weeks of age. 49 phenotype and decreased functioning of GLT-1. 50 Aberrant GLT-1 functioning might compromise the dynamics of synaptic transmission, as recently described. 15 The authors showed that the membrane diffusion of GLT-1 is a critical factor in shaping synaptic transmission. Based on these findings, it is possible that deficient function of this transporter may underlie some of the altered neuronal processing described in R6/2 mice and in other HD mouse models. 9, [23] [24] [25] 48 As previously reported, CPNs in the R6/2 model present changes in GLT-1 as early as eight weeks of age. 24 In this study, we examined the effects of inhibiting GLT-1 with the selective inhibitor DHK and evaluated the changes in the frequency of sEPSCs. Interestingly, no significant changes in the frequency of sEPSCs or the presence of paroxysmal activity occurred in R6/2 mice.
Considering that recording sEPSCs may be a passive way to measure the CPN response to further inhibition of GLT-1, we decided to challenge the neurons by applying electrical stimuli that would lead to the phasic release of glutamate and potential spillover from the synaptic cleft. Surprisingly, instead of increasing the amplitude, area, and decay time of the evoked response, which typically occurs when a high concentration of glutamate is present in the synaptic cleft, we observed the opposite; DHK inhibition of GLT-1 induced a small reduction in peak amplitude, area, and decay time in both WT and R6/2 CPNs. This effect suggests that a compensatory mechanism might have taken place and that GLAST could compensate for the compromised functioning of GLT-1. Interestingly, changes in protein content of GLAST have been less consistent. While some studies reported no change, 17, 18 others have found reduced levels in R6/2 mice at 14 weeks of age but not earlier. 21 In line with this observation, the sole inhibition of GLAST with UCPH-101 failed to reduce the glutamate response peak amplitude, as occurred during the selective blockade of GLT-1. The possibility that upregulation of GLAST function compensates for GLT-1 deficiency might serve to clarify some controversies regarding GLT-1 function in HD. For example, Petr and colleagues described that reduced expression of GLT-1 in the R6/2 model does not worsen the progression of the phenotype. 51 Moreover, an in vitro experiment evaluating glutamate clearance in striatum showed normal and even accelerated striatal reuptake in the R6/2 model. 52 More recently, it was demonstrated that GLT-1 inhibition by DHK slows clearance rates to only a small fraction (~20%)
of that produced by DL-TBOA, suggesting that non-GLT-1 transporters make a significant contribution to glutamate clearance, in particular when GLT-1 is dysfunctional, as occurs in HD. 53 These observations are compatible with our finding that, in spite of selective inhibition of GLT-1 in HD frontal cortex, the remaining transporter appears to be working more efficiently. It also suggests that slower eEPSC decay time in R6/2 mice is not due exclusively to deficient glutamate transport but also possibly due to postsynaptic changes in glutamate receptor subunits and localization. 54 These results emphasize that more experiments are needed to understand further the role of GLAST in HD neuropathology. If GLAST can cope and compensate for the failure of GLT-1, it might be a possible target for future therapeutic approaches.
Interestingly, studies in primary astrocyte cultures from cortex demonstrated that expression of mHtt in astrocytes significantly decreased both mRNA and protein levels of GLT-1 but not those of GLAST. 55 
| CON CLUS IONS
In summary, our results support the emerging understanding of the role of astrocytes in the neuropathology of HD. 56 Changes in the expression and functioning of both glutamate transporters might play a critical role during the onset and progression of HD. However, further studies are necessary to fully understand the effect of GLT-1
and GLAST alterations on neuronal functioning in vivo. Finally, the study of GLAST as it pertains to HD might bring forth a broader understanding of the roles of the glutamate reuptake system and astrocytes during HD pathogenesis.
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